Evidence map›Paper›PMID 42773154›Full record

ArticleNature communications2026

Plasma metabolomic signatures enable the diagnosis and prognosis of chronic obstructive pulmonary disease.

Chen Li, Jie Yao, Fan Wu, Leqing Zhu, Xiaowen Zhang, Lanzhu Peng, Jieda Cui, Su Fang, Li Lin, Wanli Peng and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Chen Li *State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Jie Yao *State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Fan Wu *State Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.ORCID http://orcid.org/0000-0003-0720-4674
Leqing Zhu *Guangzhou National Laboratory, Guangzhou, China.
Xiaowen ZhangKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Lanzhu PengKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Jieda CuiGuangzhou National Laboratory, Guangzhou, China.
Su FangGuangzhou National Laboratory, Guangzhou, China.
Li LinGuangzhou National Laboratory, Guangzhou, China.
Wanli PengGuangzhou National Laboratory, Guangzhou, China.
Miao LeiGuangzhou National Laboratory, Guangzhou, China.
Mingmeng FangGuangzhou National Laboratory, Guangzhou, China.
Cuihua WangGuangzhou National Laboratory, Guangzhou, China.
Bin ChenGuangzhou National Laboratory, Guangzhou, China.
Zongzheng GuiGuangzhou National Laboratory, Guangzhou, China.ORCID http://orcid.org/0009-0005-5122-3110
Xianju WangGuangzhou National Laboratory, Guangzhou, China.
Yubei JinGuangzhou National Laboratory, Guangzhou, China.
Biying ZhuGuangzhou National Laboratory, Guangzhou, China.
Chunyan LuState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Qi WanState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Xiaohui WuState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Gaoying TangState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China.
Xinru RanGMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou, China.
Wei RaoKey Laboratory of Respiratory Disease of Zhejiang Province, Department of Respiratory and Critical Care Medicine of the Second Affiliated Hospital, Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China.
Lei WangState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. leiwang2021@gzhmu.edu.cn.
Yumin ZhouState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. zhouyumin410@126.com.ORCID http://orcid.org/0000-0002-0555-8391
Pixin RanState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. pxran@gzhmu.edu.cn.ORCID http://orcid.org/0000-0001-6651-634X
Wenxiang HuState Key Laboratory of Respiratory Disease, National Clinical Research Centre for Respiratory Disease, National Centre for Respiratory Medicines, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China. hu_wenxiang@gzlab.ac.cn.ORCID http://orcid.org/0000-0002-6754-5625

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a progressive heterogeneous lung disease driving global illness and death, yet reliable biomarkers for its early diagnosis, molecular subtyping and prognosis are lacking. Here, we conduct targeted plasma metabolomic profiling in two independent, deeply phenotyped cohorts comprising 1344 participants across the full spectrum of COPD severity, with 3-year longitudinal follow-up for 651 subjects. Machine learning integration screens metabolite signatures associated with disease presence, clinical subtypes, and longitudinal outcomes. We identify unique plasma metabolic profiles distinguish COPD patients from healthy people and separate emphysema and small-airway-dominant subtypes with high accuracy in test and validation cohorts. A 27-metabolite panel detects early COPD by capturing metabolic shifts prior to lung function loss. Moreover, specific metabolite subsets independently predicted lung function decline, occurrence of acute exacerbations, and dyspnoea severity. Together, plasma metabolomics yields robust multi-purpose COPD biomarkers, offering an accessible strategy for early screening and personalized clinical risk stratification.

Indexed as

MetabolomeMetabolomicsPulmonary Disease, Chronic ObstructiveAgedBiomarkersFemaleHumansLongitudinal StudiesMaleMiddle AgedPrognosisBiomarkers

Identifiers

PMID42773154
PMCPMC13598146

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.